Inflammation — Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
Citation(s)
23 Carlsson R, Bolling E, Jerndal , et al. Factors predicting response to omeprazole treatment in patients with functional dyspepsia. Gastroenterology 1996;110:A76.
Agréus L Natural history of dyspepsia. Gut. 2002 May;50 Suppl 4:iv2-9. Review.
Collen MJ, Lewis JH, Benjamin SB Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology. 1990 Mar;98(3):654-61.
Collen MJ, Loebenberg MJ Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis. Dig Dis Sci. 1989 Feb;34(2):246-50.
Fletcher J, Wirz A, Henry E, McColl KE Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut. 2004 Feb;53(2):168-73.
George AA, Tsuchiyose M, Dooley CP Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia. Gastroenterology. 1991 Jul;101(1):3-6.
Hirschowitz BI A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology. 1991 Nov;101(5):1149-58.
Hirschowitz BI Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci. 1996 Jul;41(7):1384-91.
Hirschowitz BI Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls. Dig Dis Sci. 1996 Nov;41(11):2115-22.
Johnston BT, Collins JS, McFarland RJ, Love AH Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am J Gastroenterol. 1994 Apr;89(4):497-502.
Talley NJ, Lauritsen K The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut. 2002 May;50 Suppl 4:iv36-41.
Talley NJ, Phillips SF Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med. 1988 Jun;108(6):865-79. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
